Oncoinvent ASA
Oncoinvent ASA is a biotechnology company focused on the development of novel therapies for the treatment of cancer, leveraging its proprietary platform to discover and develop small molecule drugs.
Business. Oncoinvent ASA (ONCIN.OL) is a biotechnology and medical research company headquartered in Norway. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. It is primarily listed on the Oslo Børs. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
2 analysts · consensus Buy- EarningsH1 2026 earnings (expected)2026-08-27 · estimated
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsH1 2026 earnings (expected)2026-08-27 · estimated
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Oncoinvent ASA (ONCIN.OL) is a biotechnology and medical research company headquartered in Norway. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. It is primarily listed on the Oslo Børs. Specific details regarding operating segments and geographic revenue mix are not available.
Oncoinvent ASA maintains a strong liquidity position, with cash and equivalents amounting to NOK 177.6 million, significantly exceeding its total liabilities of NOK 58.6 million, resulting in a current ratio of 3.23. The company's debt-to-equity ratio is 0.02, indicating minimal leverage and a conservative capital structure.
The company's profitability metrics are currently negative, with a return on equity of -105.98% and a return on assets of -75.66%. These figures suggest that Oncoinvent is not generating returns for its shareholders or effectively utilizing its assets to generate profit, which is a common characteristic for early-stage biotechnology firms.
Oncoinvent's revenue for the latest period is NOK 28.1 million, with no disclosed segment or geographic breakdown in the provided data. The company's operations are likely concentrated in a few key therapeutic areas, as is typical for biotechnology firms in the early stages of development.
The company's growth trajectory is not yet evident in terms of revenue, as it reported a net loss of NOK 155.1 million for the period. However, the company is investing in its operations, as evidenced by the capital expenditure of NOK 119,000. The outlook for the current and next fiscal years is not provided in the data, but the company's ongoing research and development efforts may indicate a long-term growth strategy.
The risk assessment for Oncoinvent indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is also low, and no adjustments have been applied to its valuation metrics. This suggests that the company is not currently under pressure to raise additional capital through equity issuance.
Recent events related to Oncoinvent include the latest financial filing, which provides the most recent financial snapshot. There are no disclosed recent filings or transcripts that would indicate significant changes in the company's operations or strategic direction.
- Oncoinvent ASA has a strong liquidity position with a current ratio of 3.23 and a low debt-to-equity ratio of 0.02.
- The company is currently unprofitable, with a return on equity of -105.98% and a return on assets of -75.66%.
- Oncoinvent's revenue for the latest period is NOK 28.1 million, with no disclosed segment or geographic breakdown.
- The company's growth trajectory is not yet evident in terms of revenue, as it reported a net loss of NOK 155.1 million for the period.
- The risk assessment for Oncoinvent indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,54 |
| Revenue | —no estimate | —no estimate | 27,5M NOK |
| Operating income | —no estimate | —no estimate | -171,5M NOK |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Oncoinvent ASA Market data — financials · 2026-05-28
- Oncoinvent ASA Market data — analyst estimates · 2026-05-28
Ownership & reference
Leadership
- Øystein SougCEO
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Current ratio (FY 2024-12-31): 5.32xDerived (calculated)
- Net margin (FY 2024-12-31): -7,329.8%Derived (calculated)
- Return on equity (FY 2024-12-31): -114.1%Derived (calculated)
- Return on assets (FY 2024-12-31): -92.2%Derived (calculated)
- Debt-to-equity (FY 2024-12-31): 0.24xDerived (calculated)
- Current liabilities (annual): NOK 28.3MBRREG filing
- Net income (annual): NOK -139.93MBRREG filing
- Pre-tax income (annual): NOK -139.93MBRREG filing
- Operating income (annual): NOK -152.5MBRREG filing
- Revenue (annual): NOK 1.91MBRREG filing
- Total operating expenses (annual): NOK 154.41MBRREG filing
- Finance expense (annual): NOK 3.96MBRREG filing
- Total assets (annual): NOK 151.78MBRREG filing
- Current assets (annual): NOK 150.53MBRREG filing
- Non current assets (annual): NOK 1.25MBRREG filing
- Total equity & liabilities (annual): NOK 151.78MBRREG filing
- Shareholders' equity (annual): NOK 122.66MBRREG filing
- Total liabilities (annual): NOK 29.12MBRREG filing
- Non current liabilities (annual): NOK 818KBRREG filing